PRIMARY STUDY

Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease.

Key Findings:  Downregulation of CB2 receptors has been reported in the brains of PD patients. Therefore, both the activation and the upregulation of the CB2 receptors are believed to protect against the neurodegenerative changes in PD. The present study suggests that BCP has the potential therapeutic efficacy to elicit significant neuroprotection by its anti-inflammatory and antioxidant activities mediated by activation of the CB2 receptors.

Type of Study:  Animal Study

Study Result:  Positive


Cannabinoids Studied:  AM-x Synthetic Cannabinoids

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Injection

Dosage: BCP was diluted in olive oil and administered i.p. at a dose of 50 mg/kg BW once daily for 4 weeks, 30 min prior to rotenone (ROT) administration in the presence or absence of AM630, a CB2 receptor antagonist.

Terpenes Studied:  ß-Caryophyllene

Receptors Studied:  CB2

Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines


Study Location(s):  Australia, Italy, United Arab Emirates

Year of Pub:  2016


Link to study